Limb lengthening success rate: four definitions, four different numbers

The lengthening literature has never agreed on one outcome. Dror Paley’s 1990 series of 60 segments in 46 patients set the vocabulary still in use: a problem is a difficulty solved in clinic without surgery, an obstacle needs an operation to fix, and a complication is an intraoperative injury or anything still unresolved when treatment ends. In that series the surgical goal was met in 57 of 60 segments and 94% of patients were satisfied. The same 60 segments generated 35 problems, 11 obstacles and 27 true complications, 10 of them major. Every number is correct. They measure different things.

The nail literature uses the Black classification instead: Type I needs minimal intervention, Type II changes the treatment plan, Type IIIA means the lengthening goal was not reached, Type IIIB means a new pathology or permanent sequelae. A clinic quoting 98% success is counting satisfaction or union. A paper quoting 53% complications is counting every Type I pin problem. Neither is lying. The table sets out the five definitions this article uses and the best available number for each.

Length is the outcome patients pay for, and the one surgery delivers most reliably. In the 2021 Acta Orthopaedica review of 983 FITBONE and PRECICE segments, 5% of segments failed to reach the lengthening goal because of a complication; 95% got there. Novikov’s cosmetic Ilizarov cohort grades outcome by how much of the plan was achieved: 72 patients (55%) excellent, meaning full planned length with normal joints and alignment; 52 (40%) good, meaning planned length with a minor gait, alignment or motion deficit; 6 (4.58%) satisfactory, meaning at least 75% of the plan; and 1 (0.77%) poor, a patient who stopped at 2 cm.

The size of the plan matters as much as whether it is met. Marwan’s 2020 systematic review of 795 cosmetic patients found a mean gain of 6.7 cm, range 1.5 to 13.0 cm. Giorgino’s 2025 review of 760 patients found study means between 62 and 87 mm, average 67 mm. Novikov’s patients gained a mean 6.9 cm, 7.3 cm in men and 6.5 cm in women. The literature has delivered 6 to 7 cm per segment. The Paley Institute’s stature center puts the safe ceiling at 8 cm in the femur and 5 cm in the tibia; plans beyond that fill the complication columns below.

Union is the surgeon’s definition. New bone in the distraction gap has to consolidate before full weight-bearing, measured as days of treatment per centimetre gained. Marwan’s review reports a mean consolidation index of 36.8 days per cm and a mean external fixation index of 29.2 days per cm, range 6.3 to 180. Novikov’s cohort wore the frame a mean 215 days, range 71 to 390, at 31 days per cm. For a 7 cm plan that is seven months in the frame.

Failure of union is rare but not zero. In the 983-segment nail review, delayed healing occurred in 46 segments (5%) and premature consolidation, the bone bridging before the plan is complete, in 19 (2%). Novikov recorded delayed regeneration in 6 of 131 patients (4.58%), osteomyelitis in 3 (2.29%) and one late fracture (0.76%). Giorgino’s 2025 review counted 100 bone-related mentions across 760 patients, with nonunion in 3.

Where union fails, the picture changes. A 2024 specialized-center revision series of 9 patients (18 limbs, 22 bones) referred after cosmetic lengthening performed elsewhere found malunion or nonunion in 9 of 22 bones (45%), hardware failure in 5 (23%) and iatrogenic deformity in 4. A series of failures, not a rate, but it shows what a missed consolidation costs: more operations and months.

This is the definition behind the frightening headlines, and where counting rules matter most. Novikov’s 131 cosmetic Ilizarov patients had 59 complications in 48 patients (37%); 23 patients (18%) needed a reoperation and 6 (4.58%) kept a residual deficit at a mean six years of follow-up. The 983-segment nail review found 332 complications, 34% of segments: 11% Type I, 15% Type II, 5% Type IIIA and 3% Type IIIB. The 2023 cohort of 314 nails in 257 patients, mostly FITBONE and 80% femur, found complications in 53% of patients.

Marwan’s review frames the same events per patient across 795 cosmetic cases: 0.78 problems, 0.94 obstacles and 0.15 true complications each, and concludes that the rate of serious major complications is low. Giorgino’s 2025 review could not pool at all because its 12 studies counted differently, so it reports mentions: 425 joint or tendon, 197 infection, 100 bone, 90 pain, 82 device, 43 nerve or vessel, across 760 patients. Read together: most patients have at least one event, most events are Type I or II, and roughly one segment in twelve ends with a missed goal or lasting harm. The limb lengthening complication rate and the success rate are the same data read from opposite ends.

A patient can reach the planned length, consolidate on schedule, and still count the surgery a failure if the ankle no longer dorsiflexes. Joint and tendon problems are the largest complication category in every cosmetic series: 425 mentions across Giorgino’s 760 patients, with 94 equinus contractures recorded in the 125-patient bilateral tibia cohort and 42 in a 63-patient 2016 Ilizarov tibia series (counts, not rates: the review notes that studies counted per patient or per limb inconsistently). In the nail literature, joint contracture affected 53 of 983 segments (5%) and made up 51 of the 72 joint complications in the 2023 cohort.

Most of it resolves. Novikov’s residual deficits at final follow-up were 6 of 131: four with limited ankle dorsiflexion, one knee flexion deformity, one peroneal palsy. The best functional dataset is Park’s 125 bilateral cosmetic tibia patients (LATN, LON or ISKD). Sports (SARS) and knee (IKDC) scores fell at one year and recovered to pre-operative levels at two. Self-reported ability at two years averaged 94.6 out of 100 for daily living and 89.9 for light sports, but only 68.1 for moderate-to-strenuous sport, and 39 patients (31.2%) scored below average there. Walking, stairs and gym work come back for nearly everyone. Competitive sport is the definition on which about a third of tibia patients fall short.

Satisfaction is the number clinics quote, and it is genuinely high. Novikov: 130 of 131 patients satisfied, with improved self-esteem, at a mean six years. Giorgino’s review: satisfaction between 88.8% and 98% across the studies that measured it, including 9 of 9 in a small motorized-nail series and 94% at one year in a 32-patient LATN series. Marwan’s review states that most patients were satisfied and had excellent functional outcomes.

Two cautions. First, the instruments. Marwan notes that several studies used unvalidated outcome scores and some omitted consolidation data, which makes the figures hard to compare. Giorgino scored most included studies between 7 and 13 on a 16-point quality scale and found no randomised trials. Second, the timing. Park’s cohort was worse at one year than before surgery on both functional scales measured and only recovered at two; a satisfaction survey at 12 months and one at 24 months describe different patients. The honest reading of cosmetic limb lengthening outcomes is that roughly nine in ten patients end up glad they did it, measured by each study’s own yardstick, in cohorts that were followed and answered.

Method changes the type of complication more than the total. Frames put the risk at the skin: pin-site infections numbered 26 in a 54-patient 2005 Ilizarov tibia series, 25 in a 63-patient 2016 series, 65 in a 143-patient 2014 LON cohort and 21 in a 32-patient 2015 LON series. Motorized nails move it inside the bone: infection fell to 0.8% of 983 segments while device-related events became the largest category at 12%, and PRECICE segments had fewer complications than FITBONE (31% versus 46%). Marwan found the lowest problem, obstacle and complication counts with implantable nails, but the difference was not statistically significant.

Patient factors are best documented in the 2023 nail cohort. Tibia lengthening carried a 70% higher complication risk than femur (RR 1.7, CI 1.4 to 2.0). Patients over 30 had roughly double the risk of the 10 to 19 group: RR 2.1 at 30 to 39 and 2.6 at 50 to 59. A short-stature indication itself raised risk by 80% (RR 1.8, CI 1.2 to 2.8), which is the cosmetic patient. Extra millimetres added about 1% each in the crude model, not after adjustment. The revision series adds a fifth factor without a rate: its 9 referred patients had their index surgery in Turkey (3), Greece (2), Germany (1), the continental US (1) and unknown locations (2), and the authors flag rising complications from medical tourism.

Any clinic can produce a limb lengthening success rate above 95% by choosing the definition. Ask which one. Five questions turn a marketing number into a comparable one. What counts as success: length reached, union, no reoperation, or satisfaction? What is the denominator: patients, limbs or segments, over which years? How many patients were lost before the last follow-up? How are complications classified, Paley or Black, and what is the Type II and Type III share? What is the reoperation rate, the figure that costs patients money and months?

A surgeon who answers with a table, an n and a follow-up period is quoting outcomes. One who answers with over 98% and no denominator is quoting satisfaction, probably from patients who came back. The published limb lengthening success rate, honestly stated, runs like this: 95% of segments reach the length, roughly nine in ten patients are satisfied, one in two or three has a complication of some kind, 18% needed another operation in the largest frame series, and 3% to 5% carry a permanent deficit. Compare a clinic’s own figures against those, ask for its Type III cases, and choose from surgeons who publish theirs.